News archives

These are the news articles that are older than a year.  For the latest news, please visit the latest news page.

Page 4 of 12

<< Prev   1 2 3 4 5 6 7 8 9 10 11 12   Next >>

Board Appointment

21 July 2006

Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (”Phytopharm”) announces the appointment with immediate effect of Dr Peter Robin Blower, former Director of New Neuroscience products at SmithKline Beecham as a non-executive Board Director of Phytopharm.

Appointment of Non Executive Director

5 June 2006

Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (”Phytopharm”) announces the appointment with immediate effect of Mr A D (Sandy) Morrison, former CEO of Lipton Ltd (a Unilever subsidiary) as a Non-executive Board Director of Phytopharm.

Launch of Phytopica™

24 April 2006

Phytopharm responsible for manufacture and Schering-Plough Animal Health for marketing and distribution

Phytopharm successfully progresses to second stage of Joint Development Agreement for Hoodia gordonii extract with Unilever

10 April 2006

Second stage includes clinical safety studies

Phytopharm plc and Schering-Plough Animal Health enter into a Marketing and Distribution Agreement for Phytopica™

9 January 2006

PHYTOPHARM PLC AND SCHERING-PLOUGH ANIMAL HEALTH ENTER INTO A MARKETING AND DISTRIBUTION AGREEMENT FOR PHYTOPICA(TM)

Preliminary trial results expected December 2005

30 November 2005

Phytopharm plc (LSE:PYM; NASDAQBB: PHYOF; PHYOY) (’Phytopharm’) announces today that all subjects have now completed their participation in the phase II proof of principle clinical study of PYM50028 (CoganeTM). The compound is an orally active, synthetic, neuroprotective and neurotrophic product that is under development as a treatment for Alzheimer’s disease.

Board Change

30 November 2005

Phytopharm announced on 3rd November 2005 that Dr G W Chong is to step down as a director and Chief Financial Officer to pursue other interests and that this was expected to take effect at the latest on 3 May 2006. Dr Chong will now cease to be a director and Chief Financial Officer on 2nd December 2005.

Preliminary results of Phase II proof of principle study in Alzheimer's disease

28 November 2005

Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (’Phytopharm’) announces today the preliminary results obtained from the Phase II proof of principle clinical study of PYM50028

Resignation of Joint Sponsor and Broker

23 June 2005

The Company announces that Canaccord Capital (Europe) Limited has resigned as the company’s joint sponsor and broker with immediate effect.

Interim results for the period to 28 February 2005

11 May 2005

Phytopharm plc has announced their Interim Results for the period to 28 February 2005.

Page 4 of 12

<< Prev   1 2 3 4 5 6 7 8 9 10 11 12   Next >>